SLC9A3 and diabetes mellitus: GLP-1 analogs stimulate natriuresis at physiological levels by inhibiting sodium reabsorption via decreased activity of sodium–hydrogen exchanger 3 (NHE3) or solute carrier family 9 member 3 (SLC9A3) in the proximal tubules, resulting in decreased blood pressure in patients with diabetes [68,69].